Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Champs, C.
Right arrow Articles by Sirot, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Champs, C.
Right arrow Articles by Sirot, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 537-539
© 2000 The British Society for Antimicrobial Chemotherapy


Brief reports

Clinical relevance of Proteus mirabilis in hospital patients: a two year survey

C. de Champs*, R. Bonnet, D. Sirot, C. Chanal and J. Sirot

Laboratoire de Bactériologie, Faculté de Médecine, 28, place Henri Dunant, 63001 Clermont-Ferrand Cedex, France

A retrospective study was performed on 1072 non-duplicate isolates of Proteus mirabilis, taken in the period April 1996 to March 1998, and on 100 patient charts randomly selected during the same period. P. mirabilis isolates accounted for 7.7% of Enterobacteriaceae. The isolates were predominantly from urine (70.2%); of the total, 38.0% were penicillinase-producing isolates, 6.9% were extended-spectrum ß-lactamase (ESBL)-producing isolates and 3.6% produced inhibitor-resistant ß-lactamase (IRB). ESBL-producing isolates were observed in long-stay and intensive care and IRB-producing isolates in paediatric units. Of the 95 patients whose charts were examined, 69 had a confirmed infection, which in 42 cases was nosocomial.

* Corresponding author. Tel: +33-4-73-60-80-18; Fax: +33-4-73-27-74-94; E-mail: Christophe.DECHAMPS{at}u-clermont1.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
R. Saito, K. Sato, W. Kumita, N. Inami, H. Nishiyama, N. Okamura, K. Moriya, and K. Koike
Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis
J. Antimicrob. Chemother., September 1, 2006; 58(3): 673 - 677.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
F. Luzzaro, M. Mezzatesta, C. Mugnaioli, M. Perilli, S. Stefani, G. Amicosante, G. M. Rossolini, and A. Toniolo
Trends in Production of Extended-Spectrum {beta}-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey.
J. Clin. Microbiol., May 1, 2006; 44(5): 1659 - 1664.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. Endimiani, F. Luzzaro, G. Brigante, M. Perilli, G. Lombardi, G. Amicosante, G. M. Rossolini, and A. Toniolo
Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum {beta}-Lactamases
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2598 - 2605.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
N. Nagano, N. Shibata, Y. Saitou, Y. Nagano, and Y. Arakawa
Nosocomial Outbreak of Infections by Proteus mirabilis That Produces Extended-Spectrum CTX-M-2 Type {beta}-Lactamase
J. Clin. Microbiol., December 1, 2003; 41(12): 5530 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
T. Naas, M. Zerbib, D. Girlich, and P. Nordmann
Integration of a Transposon Tn1-Encoded Inhibitor-Resistant {beta}-Lactamase Gene, blaTEM-67 from Proteus mirabilis, into the Escherichia coli Chromosome
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 19 - 26.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. H Mutnick, J. T Kirby, and R. N Jones
CANCER Resistance Surveillance Program: Initial Results from Hematology-Oncology Centers in North America
Ann. Pharmacother., January 1, 2003; 37(1): 47 - 56.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. M. Weigel, G. J. Anderson, and F. C. Tenover
DNA Gyrase and Topoisomerase IV Mutations Associated with Fluoroquinolone Resistance in Proteus mirabilis
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2582 - 2587.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
T. Spanu, F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, and G. Fadda
Occurrence of Extended-Spectrum {beta}-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to {beta}-Lactams and Other Antimicrobial Drugs
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 196 - 202.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. de Champs, C. Monne, R. Bonnet, W. Sougakoff, D. Sirot, C. Chanal, and J. Sirot
New TEM Variant (TEM-92) Produced by Proteus mirabilis and Providencia stuartii Isolates
Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1278 - 1280.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
C. Chanal, R. Bonnet, C. De Champs, D. Sirot, R. Labia, and J. Sirot
Prevalence of beta -Lactamases among 1,072 Clinical Strains of Proteus mirabilis: a 2-Year Survey in a French Hospital
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1930 - 1935.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.